URGN - Dhuwit awis perusahaan urogen.com

Simbol resmi perusahaan UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN) operates a non-cyclical business where demand for bladder cancer therapy remains independent of pricing. The current cash balance confirms financial stability, and the parameter value is 0.09. While the diversification of gel platforms protects UroGen Pharma Ltd. (URGN) from research failures, challenges in promoting Jelmyto and the costs of certifying new treatment methods are weighing on overall profitability.

Total volume dana dhuwit perusahaan: UroGen Pharma Ltd (URGN) kanggo 04.07.2022 - 21.11.2026

Rincian analitis perusahaan UroGen Pharma Ltd.

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:URGN urogen.com
Produk merek UroGen Pharma

This metric captures the actual volume of free cash on accounts, allowing for real-time liquidity tracking between quarterly reports. For UroGen Pharma Ltd. (URGN), this capital reserve is critical when expanding the network of partner clinics; therefore, analyzing cash liquidity helps assess the company's ability to fund the commercial launch of innovative drugs without incurring new debt.

Pesaing UroGen Pharma Ltd.

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Bicara Bio - Gunggung dana dhuwit perusahaan|PSNL: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan ERAS|Dhuwit awis perusahaan DCTH|Cadangan dhuwit perusahaan Y-mAbs Therapeutics Inc YMAB|Volume dana dhuwit perusahaan AURA|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan